The myth of ‘stable’ coronary artery disease

被引:0
|
作者
Keith A. A. Fox
Marco Metra
João Morais
Dan Atar
机构
[1] University of Edinburgh,British Heart Foundation Centre for Cardiovascular Sciences
[2] University of Brescia,Department of Cardiology
[3] Leiria Hospital Centre,Institute of Clinical Sciences
[4] Oslo University Hospital Ulleval,undefined
[5] University of Oslo,undefined
来源
Nature Reviews Cardiology | 2020年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Patients with known cardiovascular disease who have not had a recent acute event are often referred to as having stable coronary artery disease (CAD). The concept of ‘stable’ CAD is misleading for two important reasons: the continuing risks of cardiovascular events over the longer term and the diverse spectrum of powerful risk characteristics. The risks of cardiovascular events are frequently underestimated and continue to exist, despite current standards of care for secondary prevention, including lifestyle changes, optimal medical therapy, myocardial revascularization and the use of antiplatelet agents to limit thrombosis. In dispelling the myth of ‘stable’ CAD, we explore the pathophysiology of the disease and the relative contribution of plaque and systemic factors to cardiovascular events. A broader concept of the vulnerable patient, not just the vulnerable plaque, takes into account the diversity and future risks of atherothrombotic events. We also evaluate new and ongoing research into medical therapies aimed at further reducing the risks of cardiovascular events in patients with chronic — but not stable — atherothrombotic disease.
引用
收藏
页码:9 / 21
页数:12
相关论文
共 50 条
  • [41] Stable coronary artery disease - case report
    Custodis, F
    Scheller, B
    Laufs, U
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (11) : 554 - 555
  • [42] Revsculariza don in Stable Coronary Artery Disease
    Sherwood, Matthew W.
    Peterson, Eric D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (19): : 2028 - +
  • [43] Controversies in revascularisation for stable coronary artery disease
    Nowbar, Alexandra N.
    Rajkumar, Christopher
    Al-Lamee, Rasha K.
    Francis, Darrel P.
    [J]. CLINICAL MEDICINE, 2021, 21 (02) : 114 - 118
  • [44] Revascularization in advanced stable coronary artery disease
    Gutstein, DE
    Fuster, V
    [J]. DRUGS OF TODAY, 1998, 34 (01) : 37 - 44
  • [45] Contemporary Management of Stable Coronary Artery Disease
    Bertolone, Dario Tino
    Gallinoro, Emanuele
    Esposito, Giuseppe
    Paolisso, Pasquale
    Bermpeis, Konstantinos
    De Colle, Cristina
    Fabbricatore, Davide
    Mileva, Niya
    Valeriano, Chiara
    Munhoz, Daniel
    Belmonte, Marta
    Vanderheyden, Marc
    Bartunek, Jozef
    Sonck, Jeroen
    Wyffels, Eric
    Collet, Carlos
    Mancusi, Costantino
    Morisco, Carmine
    De Luca, Nicola
    De Bruyne, Bernard
    Barbato, Emanuele
    [J]. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2022, 29 (03) : 207 - 219
  • [46] Serum Myeloperoxidase in Stable Coronary Artery Disease
    Belle, Vijetha Shenoy
    Shetty, K. Ranjan
    Prabhu, Krishnananda
    Prasad, Rajaram
    Rao, Pragna
    [J]. ADVANCED SCIENCE LETTERS, 2017, 23 (03) : 1785 - 1788
  • [47] Management of stable chronic coronary artery disease
    Achenbach, S.
    [J]. HERZ, 2015, 40 (04) : 645 - 654
  • [48] Stable coronary artery disease - diagnostics and therapy
    Laufs, U
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (11) : 556 - 562
  • [49] Almanac 2013: stable coronary artery disease
    Islam, Shahed
    Timmis, Adam
    [J]. HEART, 2013, 99 (22) : 1652 - 1657
  • [50] ACE inhibitors in stable coronary artery disease
    Nitschmann, S
    [J]. INTERNIST, 2004, 45 (10): : 1196 - 1197